FindTrial
Sign In

Role of Midregional proadrenomedullin in detecting infection in newborn children

Evaluation of Midregional Proadrenomedullin as a diagnostic and prognostic marker of neonatal sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/04/033251
Enrollment
100
Registered
2021-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P369- Bacterial sepsis of newborn, unspecified

Interventions

Intervention1: NIL: NIL

Sponsors

Sri Devaraj Urs Academy of Higher Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All term singleton newborn admitted to Neonatal intensive care unit (consists of intramural and extramural newborns) requiring intravenous antibiotics

Exclusion criteria

Exclusion criteria: Maternal preeclampsia Birth asphyxia Intracranial bleed Persistent pulmonary hypertension of newborn Surgical disorders

Design outcomes

Primary

MeasureTime frame
Critical value of midregional proadrenomedullin for diagnosis of neonatal sepsisTimepoint: At 0 hours/birth and after 48 hours—

Secondary

MeasureTime frame
Compare Midregional proadrenomedullin with sepsis screen to determine outcome in neonatal sepsisTimepoint: At 0 hour/birth and after 48 hours—

Countries

India

Contacts

Public ContactShivaraja A

Sri Devaraj Urs Academy of Higher Education and Research

dr.shivaraja@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026